0002092017-26-000005.txt : 20260603 0002092017-26-000005.hdr.sgml : 20260603 20260603200234 ACCESSION NUMBER: 0002092017-26-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260601 FILED AS OF DATE: 20260603 DATE AS OF CHANGE: 20260603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Jeegar Pravinkumar CENTRAL INDEX KEY: 0002092017 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42938 FILM NUMBER: 261062817 MAIL ADDRESS: STREET 1: 1841 PAGE MILL ROAD, SUITE 100 CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evommune, Inc. CENTRAL INDEX KEY: 0002044725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 850742575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1891 PAGE MILL RD CITY: PALO ALTO STATE: CA BUSINESS PHONE: (650) 223-7745 MAIL ADDRESS: STREET 1: 1891 PAGE MILL RD CITY: PALO ALTO STATE: CA 4 1 primarydocument.xml PRIMARY DOCUMENT X0609 4 2026-06-01 false 0002044725 Evommune, Inc. EVMN 0002092017 Patel Jeegar Pravinkumar false C/O EVOMMUNE, INC. 1891 PAGE MILL ROAD PALO ALTO CA 94304 false true false false Chief Scientific Officer true Common Stock 2026-06-01 4 M false 13512.00 3.84 A 63090.00 D Common Stock 2026-06-01 4 S false 16687.00 22.74 D 46403.00 D Employee Stock Option (Right to Buy) 3.84 2026-06-01 4 M false 13512.00 0.00 D 2033-05-11 Common Stock 13512.00 29330.00 D The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. /s/ Gregory S. Moss, Attorney-in-Fact 2026-06-03